ReSurfX News

ReSurfX is proud to announce an agreement with a leading healthcare system to provide our solutions to a variety of problems. We believe this agreement will bring novel cost saving products and solutions for personalized and evidence based medicine to the healthcare marketplace with additional advantages and recognition to early adopters. We are also targeting to help research units make novel discoveries more effectively using our solutions.

Releasing our first web application product ReSurfX::vysen showcasing our novel 'Adaptive Hypersurface Technology' as a prelude to enterprise grade integrative analytics platform enabling better decisions and outcomes. This initial beta product is targeted towards data from a single gene expression technology.

ReSurfX selected as an 'emerging company defining the next generation of personalized medicine platforms and technologies' at the Personalized Medicine World Conference (PMWC2013) in Silicon Valley January 28-29, 2013. We presented our novel platform for better data generation and utilization and our newest configuration that becomes an "Advance Outcomes Alert System' and their applications in drug development and patient care outcomes.

ReSurfX Inc. is proud to support the Big Data Summit:  The Big Data Disruption by MassTLC on February 15, 2012. We are proud to continue to provide value to the ‘Big Data’ problems in unique ways through innovative measurement system designs and enterprise grade analytic solutions for increased ROI through reduced errors in data utilization. This Exhibitor/Showcase sponsorship shows our commitment to be a leading edge player in this vibrant ecosystem to solve major problems involving ‘Big Data’.

ReSurfX LLC merges into ReSurfX, Inc. We strive to be a lasting enterprise solving significant problems in the generation and utilization of large volumes of data (‘Big Data’), and creating value in drug discovery and development, healthcare and beyond. We continue to make our products and solutions available to other sectors including finance, targeted marketing, large volume use consumer technologies (e.g., smartphone based sensors), manufacturing, QC etc.

ReSurfX welcomes Dr. Shahin Ghara­khanian, MD DPH to our advisory board.  Dr. Gharakhaninan is a Pharmaceutical Medicines and Infectious Diseases expert and will be participating in application of our technologies to Clinical Trials and in Drug Discovery and Development. Dr. Gharakhanian will be joining our other experts Joseph Sabatini (Corporate Development), Dr. Sandeep Kochhar (Software architecture, Datawarehousing and BI) and our CEO - Dr. Suresh Gopalan.

ReSurfX receives ‘Angel Investment’ to continue developing the venture. We are thankful to the investor who at this point would like to remain anonymous.

ReSurfX Showcased as one of the “30 Exciting Early-Stage Technology Startups” at the Entrepreneur Showcase part of 13th Annual MIT Venture Capital Conference – “Here and Now: The Present of Venture Capital and Entrepreneurship” - on November 19, 2010.

1 2 3